Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects
- Conditions
- Hypocalcemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2006-08-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 45
- Registration Number
- NCT00053378
- Locations
- 🇺🇸
St. Luke's Hospital, Bethlehem, Pennsylvania, United States
🇺🇸Merced Heart Association, Merced, California, United States
🇺🇸Central Baptist Hospital Clinical Research Center, Lexington, Kentucky, United States
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
- Conditions
- Renal Insufficiency, Chronic
- First Posted Date
- 2002-11-04
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 68
- Registration Number
- NCT00048438
- Locations
- 🇺🇸
Nephrology Association of South Miami, Miami, Florida, United States
🇺🇸Dallas Nephrology Associates, Dallas, Texas, United States
🇺🇸Arms, Dodge, Robinson, Wilber and Crouch, Kansas City, Missouri, United States
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
- Conditions
- Renal Insufficiency, Chronic
- First Posted Date
- 2002-11-04
- Last Posted Date
- 2006-08-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 68
- Registration Number
- NCT00048516
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇵🇱Wojewodzki Szpital Specjalistyczny AM w Bialymstoku, Bialymstoku, Poland
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, Los Angeles, California, United States
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
- Conditions
- Renal Insufficiency, Chronic
- First Posted Date
- 2002-11-04
- Last Posted Date
- 2006-08-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 68
- Registration Number
- NCT00048451
- Locations
- 🇺🇸
Medisphere Medical Research Center, Evansville, Indiana, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Biolab Research, LLC, Rockville, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.